Most Recent Articles by Steve Duffy, Digital Content Editor
The FDA has cleared a non-invasive brain stimulation system for treating depression.
There is an increased risk for ADHD in offspring born to mothers who used acetaminophen while pregnant.
The FDA has granted Orphan Drug Designation to Valbenazine.
There was a drop in PTSD symptoms with hyperbaric oxygen therapy.
Once a month Vivitrol was found to be non-inferior to daily buprenorphine-naloxone for preventing relapse to opioid dependence.
More Articles by Steve Duffy, Digital Content Editor
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Monetary Incentives Improve Cessation in Mentally Ill Smokers
- Obsessive Compulsive Disorder Associated With Decreased Educational Attainment
- Fluvoxamine Effective for Depression in Patients With Neurological Disorders
- When and How to Initiate Driving Cessation Conversation for Dementia Patients
- Memory Scores Have Limited Value as Early Alzheimer Disease Screening Tools
- Nutritional Psychiatry: Emerging Evidence and Expert Interview
- FDA Approval: Once-Monthly Buprenorphine Injection for Opioid Use Disorder
- Posttreatment Brain Effects of Psilocybin in Patients With Treatment-Resistant Depression
- Bipolar Disorder, Borderline Personality Disorder May Represent the Same Disorder
- Borderline Personality Disorder: Not Just an Adult Condition
- Depression Screening Tools Accurate in Post-Acute Coronary Syndrome
- Antidepressant Effectiveness for Depression in Schizophrenia
- Higher Rates of Psychotic Incidence in Younger Men, Racial Minorities
- Healthcare Inequality in America: Senator Bernie Sanders's Advisors on Causes and Solutions
- Code of Ethics and New Regulations for Human Research